Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Recombinant Hepatitis B Virus Vaccine · 1 trial · 2 indications
Number of participants with positive hepatitis B surface antigen (HBsAg) antibodies 4 to 8 weeks after completion of the vaccination schemes.
| Arm | Type | Description |
|---|---|---|
| Recombinant Hepatitis B Virus Vaccine (High Dose) | EXPERIMENTAL | Patients allocated to this arm will receive three doses of 40mcg each of recombinant hepatitis B vaccine (Engerix-B (R)). Doses will be administered at 0, 1 and 2 months. |
| Recombinant Hepatitis B Virus Vaccine (Standard Dose) | ACTIVE_COMPARATOR | Patients allocated to this arm will receive three doses of 20mcg each of recombinant hepatitis B vaccine (Engerix-B (R)). Doses will be administered at 0, 1 and 2 months. |
| Name | Type | Description |
|---|---|---|
| Recombinant Hepatitis B Virus Vaccine | BIOLOGICAL | - |
Inclusion Criteria: * Older than 18 years of age. * Patients infected with Human Immunodeficiency Virus (HIV) * Failed previous vaccination with a standard dose scheme of recombinant hepatitis B vaccine (20mcg at 0, 1 and 6 months). Nonresponders will be considered as those patients presenting a he...
Top 6 of 8 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Gilead Sciences, Inc. | GILD | 3 | PHASE3 | Viread, Tenofovir alafenamide |
| Vir Biotechnology, Inc. | VIR | 6 | PHASE3 | Tobevibart, Elebsiran |
| Bausch Health Companies Inc. | BHC | 1 | PHASE3 | Larsucosterol |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Daplusiran/Tomligisiran, Bepirovirsen |
| Aligos Therapeutics, Inc. | ALGS | 1 | PHASE2 | ALG-000184 |
| Precision BioSciences, Inc. | DTIL | 2 | PHASE1 | PBGENE-HBV |